Belite Bio Inc's filing for a mixed shelf offering of up to $300 million may have a neutral impact on its stock price in the short term. The offering could provide the company with additional capital for growth and expansion, but it may also dilute existing shareholders' ownership. The market's reaction to this news will depend on investors' perception of the company's growth prospects and the potential dilution effect.